12 results on '"Tonimarie Catalan"'
Search Results
2. Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE‐BMT Risk Score
- Author
-
Alexi Vasbinder, Tonimarie Catalan, Elizabeth Anderson, Catherine Chu, Megan Kotzin, Danielle Murphy, Halle Cheplowitz, Kristen Machado Diaz, Brayden Bitterman, Ian Pizzo, Yiyuan Huang, Jeffrey Xie, Christopher W. Hoeger, Rayan Kaakati, Hanna P. Berlin, Husam Shadid, Daniel Perry, Michael Pan, Radhika Takiar, Kishan Padalia, Jamie Mills, Chelsea Meloche, Alina Bardwell, Matthew Rochlen, Pennelope Blakely, Monika Leja, Mousumi Banerjee, Mary Riwes, John Magenau, Sarah Anand, Monalisa Ghosh, Attaphol Pawarode, Gregory Yanik, Sunita Nathan, John Maciejewski, Tochukwu Okwuosa, and Salim S. Hayek
- Subjects
atrial fibrillation ,bone marrow transplant ,cardiovascular disease ,heart failure ,hematopoietic stem cell transplant ,random forest ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Evidence guiding the pre‐hematopoietic stem cell transplantation (HSCT) cardiovascular evaluation is limited. We sought to derive and validate a pre‐HSCT score for the cardiovascular risk stratification of HSCT candidates. Methods and Results We leveraged the CARE‐BMT (Cardiovascular Registry in Bone Marrow Transplantation) study, a contemporary multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019 (N=2435; mean age at transplant of 55 years; 4.9% Black). We identified the subset of variables most predictive of post‐HSCT cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, heart failure, stroke, atrial fibrillation or flutter, and sustained ventricular tachycardia. We then developed a point‐based risk score using the hazard ratios obtained from Cox proportional hazards modeling. The score was externally validated in a separate cohort of 919 HSCT recipients (mean age at transplant 54 years; 20.4% Black). The risk score included age, transplant type, race, coronary artery disease, heart failure, peripheral artery disease, creatinine, triglycerides, and prior anthracycline dose. Risk scores were grouped as low‐, intermediate‐, and high‐risk, with the 5‐year cumulative incidence of cardiovascular events being 4.0%, 10.3%, and 22.4%, respectively. The area under the receiver operating curves for predicting cardiovascular events at 100 days, 5 and 10 years post‐HSCT were 0.65 (95% CI, 0.59–0.70), 0.73 (95% CI, 0.69–0.76), and 0.76 (95% CI, 0.69–0.81), respectively. The model performed equally well in autologous and allogeneic recipients, as well as in the validation cohort. Conclusions The CARE‐BMT risk score is easy to calculate and could help guide referrals of high‐risk HSCT recipients to cardiovascular specialists before transplant and guide long‐term monitoring.
- Published
- 2024
- Full Text
- View/download PDF
3. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
- Author
-
Shengyuan Luo, Alexi Vasbinder, Jeanne M. Du‐Fay‐de‐Lavallaz, Joanne Michelle D. Gomez, Tisha Suboc, Elizabeth Anderson, Annika Tekumulla, Husam Shadid, Hanna Berlin, Michael Pan, Tariq U. Azam, Ibrahim Khaleel, Kishan Padalia, Chelsea Meloche, Patrick O'Hayer, Tonimarie Catalan, Pennelope Blakely, Christopher Launius, Kingsley‐Michael Amadi, Rodica Pop‐Busui, Sven H. Loosen, Athanasios Chalkias, Frank Tacke, Evangelos J. Giamarellos‐Bourboulis, Izzet Altintas, Jesper Eugen‐Olsen, Kim A. Williams, Annabelle Santos Volgman, Jochen Reiser, and Salim S. Hayek
- Subjects
COVID‐19 ,soluble urokinase plasminogen activator receptor ,thromboembolism ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Venous thromboembolism (VTE) contributes significantly to COVID‐19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen activator receptor (suPAR) reflect hyperinflammation and are strongly predictive of outcomes in COVID‐19. Whether suPAR levels identify patients with COVID‐19 at risk for VTE is unclear. Methods and Results We leveraged a multinational observational study of patients hospitalized for COVID‐19 with suPAR and D‐dimer levels measured on admission. In 1960 patients (mean age, 58 years; 57% men; 20% Black race), we assessed the association between suPAR and incident VTE (defined as pulmonary embolism or deep vein thrombosis) using logistic regression and Fine‐Gray modeling, accounting for the competing risk of death. VTE occurred in 163 (8%) patients and was associated with higher suPAR and D‐dimer levels. There was a positive association between suPAR and D‐dimer (β=7.34; P=0.002). Adjusted for clinical covariables, including D‐dimer, the odds of VTE were 168% higher comparing the third with first suPAR tertiles (adjusted odds ratio, 2.68 [95% CI, 1.51–4.75]; P
- Published
- 2022
- Full Text
- View/download PDF
4. Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis
- Author
-
Alexi Vasbinder, YeeAnn Chen, Adrien Procureur, Allison Gradone, Tariq U. Azam, Daniel Perry, Husam Shadid, Elizabeth Anderson, Tonimarie Catalan, Pennelope Blakely, Namratha Nelapudi, Mohamad Fardous, Marie C. Bretagne, Sarah K. Adie, Kristen T. Pogue, Monika Leja, Sarah Yentz, Bryan Schneider, Leslie A. Fecher, Christopher D. Lao, Joe-Elie Salem, and Salim S. Hayek
- Subjects
Oncology ,Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
5. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
- Author
-
Alexi, Vasbinder, Elizabeth, Anderson, Husam, Shadid, Hanna, Berlin, Michael, Pan, Tariq U, Azam, Ibrahim, Khaleel, Kishan, Padalia, Chelsea, Meloche, Patrick, O'Hayer, Erinleigh, Michaud, Tonimarie, Catalan, Rafey, Feroze, Pennelope, Blakely, Christopher, Launius, Yiyuan, Huang, Lili, Zhao, Lynn, Ang, Monica, Mikhael, Kara, Mizokami-Stout, Subramaniam, Pennathur, Matthias, Kretzler, Sven H, Loosen, Athanasios, Chalkias, Frank, Tacke, Evangelos J, Giamarellos-Bourboulis, Jochen, Reiser, Jesper, Eugen-Olsen, Eva L, Feldman, Rodica, Pop-Busui, Salim S, Hayek, Kishan J, Padalia, Danny, Perry, Abbas, Bitar, Rayan, Kaakati, Beata, Samelko, Alex, Hlepas, Priya P, Patel, Xuexiang, Wang, Izzet, Altintas, Marius, Stauning, Morten, Baltzer Houlind, Mette B, Lindstrøm, Hejdi, Gamst-Jensen, Line Jee, Hartmann, Jan O, Nehlin, Thomas, Kallemose, Imran, Parvaiz, Christian, Rasmussen, Ove, Andersen, Jens, Tingleff, Maria-Evangelia, Adami, Nicky, Solomonidi, Maria, Tsilika, Maria, Saridaki, Vasileios, Lekakis, Tom, Luedde, Verena, Keitel, Eleni, Arnaoutoglou, Ioannis, Pantazopoulos, Eleni, Laou, Konstantina, Kolonia, Anargyros, Skoulakis, Pinkus, Tober-Lau, Raphael, Mohr, Florian, Kurth, Leif Erik, Sander, and Christoph, Jochum
- Subjects
Inflammation ,Male ,Advanced and Specialized Nursing ,SARS-CoV-2 ,Endocrinology, Diabetes and Metabolism ,COVID-19 ,Middle Aged ,Hospitalization ,Hyperglycemia ,Diabetes Mellitus ,Internal Medicine ,Humans ,Female ,Hospital Mortality ,Pathophysiology/Complications ,Biomarkers - Abstract
OBJECTIVE Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. RESEARCH DESIGN AND METHODS We leveraged the International Study of Inflammation in COVID-19 (ISIC), a multicenter observational study of 2,044 patients hospitalized with COVID-19, to characterize the impact of DM on in-hospital outcomes and assess the contribution of inflammation and hyperglycemia to the risk attributed to DM. We measured biomarkers of inflammation collected at hospital admission and collected glucose levels and insulin data throughout hospitalization. The primary outcome was the composite of in-hospital death, need for mechanical ventilation, and need for renal replacement therapy. RESULTS Among participants (mean age 60 years, 58.2% males), those with DM (n = 686, 33.5%) had a significantly higher cumulative incidence of the primary outcome (37.8% vs. 28.6%) and higher levels of inflammatory biomarkers than those without DM. Among biomarkers, DM was only associated with higher soluble urokinase plasminogen activator receptor (suPAR) levels in multivariable analysis. Adjusting for suPAR levels abrogated the association between DM and the primary outcome (adjusted odds ratio 1.23 [95% CI 0.78, 1.37]). In mediation analysis, we estimated the proportion of the effect of DM on the primary outcome mediated by suPAR at 84.2%. Hyperglycemia and higher insulin doses were independent predictors of the primary outcome, with effect sizes unaffected by adjusting for suPAR levels. CONCLUSIONS Our findings suggest that the association between DM and outcomes in COVID-19 is largely mediated by hyperinflammation as assessed by suPAR levels, while the impact of hyperglycemia is independent of inflammation.
- Published
- 2022
- Full Text
- View/download PDF
6. Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19
- Author
-
Alexi, Vasbinder, Chelsea, Meloche, Tariq U, Azam, Elizabeth, Anderson, Tonimarie, Catalan, Husam, Shadid, Hanna, Berlin, Michael, Pan, Patrick, O'Hayer, Kishan, Padalia, Pennelope, Blakely, Ibrahim, Khaleel, Erinleigh, Michaud, Yiyuan, Huang, Lili, Zhao, Rodica, Pop-Busui, Shruti, Gupta, Kim, Eagle, David E, Leaf, and Salim S, Hayek
- Subjects
Adult ,Male ,SARS-CoV-2 ,Cardiovascular Diseases ,Risk Factors ,Critical Illness ,Troponin I ,Humans ,COVID-19 ,Hospital Mortality ,Middle Aged ,Cardiology and Cardiovascular Medicine ,United States - Abstract
Background: Preexisting cardiovascular disease (CVD) is perceived as a risk factor for poor outcomes in patients with COVID-19. We sought to determine whether CVD is associated with in-hospital death and cardiovascular events in critically ill patients with COVID-19. Methods: This study used data from a multicenter cohort of adults with laboratory-confirmed COVID-19 admitted to intensive care units at 68 centers across the United States from March 1 to July 1, 2020. The primary exposure was CVD, defined as preexisting coronary artery disease, congestive heart failure, or atrial fibrillation/flutter. Myocardial injury on intensive care unit admission defined as a troponin I or T level above the 99th percentile upper reference limit of normal was a secondary exposure. The primary outcome was 28-day in-hospital mortality. Secondary outcomes included cardiovascular events (cardiac arrest, new-onset arrhythmias, new-onset heart failure, myocarditis, pericarditis, or stroke) within 14 days. Results: Among 5133 patients (3231 male [62.9%]; mean age 61 years [SD, 15]), 1174 (22.9%) had preexisting CVD. A total of 1178 (34.6%) died, and 920 (17.9%) had a cardiovascular event. After adjusting for age, sex, race, body mass index, history of smoking, and comorbidities, preexisting CVD was associated with a 1.15 (95% CI, 0.98–1.34) higher odds of death. No independent association was observed between preexisting CVD and cardiovascular events. Myocardial injury on intensive care unit admission was associated with higher odds of death (adjusted odds ratio, 1.93 [95% CI, 1.61–2.31]) and cardiovascular events (adjusted odds ratio, 1.82 [95% CI, 1.47–2.24]), regardless of the presence of CVD. Conclusions: CVD risk factors, rather than CVD itself, were the major contributors to outcomes in critically ill patients with COVID-19. The occurrence of myocardial injury, regardless of CVD, and its association with outcomes suggests it is likely due to multiorgan injury related to acute inflammation rather than exacerbation of preexisting CVD. Registration: NCT04343898; https://clinicaltrials.gov/ct2/show/NCT04343898 .
- Published
- 2022
7. BIOMARKER TRENDS AND OUTCOMES IN PATIENTS RECEIVING IMMUNE-CHECKPOINT INHIBITORS
- Author
-
Alexi Vasbinder, YeeAnn Chen, Allison Gradone, Tariq Azam, Daniel Perry, Husam Shadid, Elizabeth Anderson, Tonimarie Catalan, Pennelope K. Blakely, Namratha Nelapudi, Mohamad Fardous, Sarah Adie, Kristen Pogue, Monika Jacqueline Leja, Sarah Yentz, Bryan Schneider, and Salim Hayek
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
- Full Text
- View/download PDF
8. LEVELS OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AND HEART FAILURE OUTCOMES IN PATIENTS WITH TYPE-2 DIABETES AND WORSENING HEART FAILURE TREATED WITH SOTAGLIFLOZIN, A DUAL INHIBITOR OF SODIUM GLUCOSE COTRANSPORTERS 1 AND 2
- Author
-
Grace Erne, Pennelope K. Blakely, Elizabeth Anderson, Namratha Nelapudi, Medha Tripathi, Anis Ismail, Annika Tekumulla, Kingsley Amadi, Tonimarie Catalan, Alexi Vasbinder, Brayden Bitterman, Jiazi Chen, Caroline Tilley, Noor Sulaiman, Feriel Presswalla, Ian Pizzo, Nathan Meyette, Philippe Gabriel Steg, Michael Szarek, Franklin Sun, Michael Davies, Deepak L. Bhatt, Bertram Pitt, and Salim Hayek
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
- Full Text
- View/download PDF
9. MEASURING THE LEVELS OF THE CARDIAC BIOMARKER SUPAR (SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR) TO PREDICT THE RISK OF AORTIC ANEURYSMS
- Author
-
Medha Tripathi, Alexi Vasbinder, Elizabeth Anderson, Pennelope K. Blakely, Annika Tekumulla, Grace Erne, Kingsley Amadi, Tonimarie Catalan, Brayden Bitterman, Jiazi Chen, Namratha Nelapudi, Caroline Tilley, Noor Sulaiman, Feriel Presswalla, Ian Pizzo, Anis Ismail, Alina Bardwell, Kim A. Eagle, Cristen Willer, and Salim Hayek
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
- Full Text
- View/download PDF
10. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
- Author
-
the ISIC group, Salim S. Hayek, Rodica Pop-Busui, Eva L. Feldman, Jesper Eugen-Olsen, Jochen Reiser, Evangelos J. Giamarellos-Bourboulis, Frank Tacke, Athanasios Chalkias, Sven H. Loosen, Matthias Kretzler, Subramaniam Pennathur, Kara Mizokami-Stout, Monica Mikhael, Lynn Ang, Lili Zhao, Yiyuan Huang, Christopher Launius, Pennelope Blakely, Rafey Feroze, Tonimarie Catalan, Erinleigh Michaud, Patrick O’Hayer, Chelsea Meloche, Kishan Padalia, Ibrahim Khaleel, Tariq U. Azam, Michael Pan, Hanna Berlin, Husam Shadid, Elizabeth Anderson, and Alexi Vasbinder
- Abstract
Objective: Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. Research Design and Methods: We leveraged The International Study of Inflammation in COVID-19, a multicenter observational study of 2,044 patients hospitalized with COVID-19, to characterize the impact of DM on in-hospital outcomes and assess the contribution of inflammation and hyperglycemia to the risk attributed to DM. We measured biomarkers of inflammation collected at hospital admission and collected glucose levels and insulin data throughout hospitalization. The primary outcome was the composite of in-hospital death, need for mechanical ventilation, and need for renal replacement therapy. Results: Among participants (mean age, 60 years; 58.2% males), those with DM (n=686, 33.5%) had a significantly higher cumulative incidence of the primary outcome (37.8% vs. 28.6%) and higher levels of inflammatory biomarkers compared to those without DM. Amongst biomarkers, DM was only associated with higher soluble urokinase plasminogen activator receptor (suPAR) levels in multivariable analysis. Adjusting for suPAR levels abrogated the association between DM and the primary outcome (adjusted odds ratio 1.23[95%CI:0.78,1.37]). In mediation analysis, we estimated the proportion of the effect of DM on the primary outcome mediated by suPAR at 84.2%. Hyperglycemia and higher insulin doses were independent predictors of the primary outcome, with effect sizes unaffected by adjusting for suPAR levels. Conclusions: Our findings suggest that the association between DM and outcomes in COVID-19 is largely mediated by hyper-inflammation as assessed by suPAR levels, while the impact of hyperglycemia is independent of inflammation.
- Published
- 2022
- Full Text
- View/download PDF
11. Insufficient calorie intake worsens post-discharge quality of life and increases readmission burden in heart failure
- Author
-
Joanna M. Wells, Feriha Bilgen, Armella D Poggi, Mathew S. Maurer, Tonimarie Catalan, Wahida Karmally, Hannah R. Rosenblum, Stephen Helmke, Erika Trumble, Maria L. Cornellier, Sergio Teruya, Peiyu Chen, and Scott L. Hummel
- Subjects
Adult ,Male ,medicine.medical_specialty ,Aftercare ,030204 cardiovascular system & hematology ,Patient Readmission ,Article ,03 medical and health sciences ,Eating ,0302 clinical medicine ,Quality of life ,Interquartile range ,Internal medicine ,Medicine ,Humans ,030212 general & internal medicine ,Aged ,Heart Failure ,Meal ,business.industry ,medicine.disease ,Obesity ,Patient Discharge ,Calorie intake ,Malnutrition ,Heart failure ,Quality of Life ,Female ,Energy Intake ,Cardiology and Cardiovascular Medicine ,business ,Body mass index - Abstract
OBJECTIVES: Evaluate the relationship between calorie intake and post-discharge outcomes in hospitalized patients with heart failure (HF). BACKGROUND: Malnutrition increases adverse outcomes in HF, and dietary sodium restriction may inadvertently worsen nutritional intake. METHODS: In a dietary intervention trial, baseline nutritional intake in HF inpatients was estimated via Block Food Frequency Questionnaire (FFQ) and a Nutritional Risk Index (NRI) was calculated. Insufficient calorie intake was defined at
- Published
- 2020
12. INSUFFICIENT CALORIC INTAKE IS ASSOCIATED WITH POOR QUALITY OF LIFE AND READMISSION BURDEN POST-DISCHARGE IN OLDER PATIENTS WITH HEART FAILURE
- Author
-
Sergio Teruya, Tonimarie Catalan, Wahida Karmally, Peiyu Chen, Feriha Bilgen, Armella D Poggi, Hannah Rosenblum, Maria L. Cornellier, Mathew S. Maurer, Scott L. Hummel, and Stephen Helmke
- Subjects
medicine.medical_specialty ,Older patients ,Quality of life ,business.industry ,Post discharge ,Heart failure ,Emergency medicine ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,medicine.disease ,Poor quality ,Caloric intake - Abstract
Few studies have described dietary deficiencies in older patients hospitalized for heart failure (HF). We hypothesized that insufficient caloric intake (iCI) would predict poorer post-discharge quality of life (QOL) and greater readmission burden in HF. The GOURMET-HF study randomized HF inpatients
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.